Daniel Drucker
banner
danieljdrucker.bsky.social
Daniel Drucker
@danieljdrucker.bsky.social
A clinician scientist at LTRI @sinaihealth studying Glucagon, GIP, GLP-1, GLP-2, diabetes, obesity, metabolism and the gut endocrine system
Will advances in #precisionmedicine unlock the mystery of heterogeneity in inter-individual responses to GLP-1 medicines www.jci.org/articles/vie... #Genetics dm5migu4zj3pb.cloudfront.net/manuscripts/...
January 16, 2026 at 11:33 PM
Can one optimize next generation GLP-1 medicines through deconstructing of GPCR signaling? @jclinicalinvest www.jci.org/articles/vie... dm5migu4zj3pb.cloudfront.net/manuscripts/...
January 16, 2026 at 7:47 PM
GLP-1 medicines might stimulate cell proliferation in some GLP-1R+ cell types, while exerting direct and indirect effects on the Tumour MicroEnvironment. It will take time to see the overall impact on #obesity associated cancer. Free to read @NatureCancer rdcu.be/eZlv0
January 16, 2026 at 11:13 AM
Here the authors propose that the hepatic PPA1 FGF21 axis is a therapeutic target for #obesity and related metabolic disorders. diabetesjournals.org/diabetes/art... ada.silverchair-cdn.com/ada/content_...
January 16, 2026 at 3:27 AM
The L cell as an inflammation sensor. GLP-1 an enteroendocrine hormone with anti-inflammatory roles, was upregulated in the ileum of people with HIV and correlated directly with systemic cytokines but inversely with lymph node pyroptosis www.biorxiv.org/content/10.6...
January 11, 2026 at 1:02 PM
P2 #weightloss data over 13 weeks for VK2735 the once weekly GIPR-GLP1R medicine in adults with #obesity or overweight and ≥ 1 weight-related comorbidity onlinelibrary.wiley.com/doi/10.1002/...
January 10, 2026 at 12:29 PM
Congratulations to Professor Roman Hovorka, the 2025 Manpei Suzuki Prizze in #Diabetes Honoree www.mrl.ims.cam.ac.uk/news/double-... @easdnews.bsky.social
January 8, 2026 at 2:56 PM
The latest look at NAION and use of GLP-1 medicines; one additional case per approximately 2,700 treated patients diabetesjournals.org/care/article...
January 7, 2026 at 11:21 PM
Studies of #inflammation related signals from cord blood at birth reveals a protein subset that predicts #T1D with high accuracy (AUC = 0.89 ± 0.02), independently of HLA genetic risk www.nature.com/articles/s41...
January 7, 2026 at 10:48 AM
Patients with #diabetes and #cancer who received GLP-1 RA experienced superior survival outcomes and reduced rates of hospitalization compared to patients receiving metformin academic.oup.com/jcem/advance...
January 4, 2026 at 10:41 AM
A new review @jclinicalinvest illustrates the critical nature of gut-brain communication in human disease and the potential to target gut-brain pathways for therapeutic benefit www.jci.org/articles/vie...
January 3, 2026 at 11:22 AM
Studies in mice and human #islets identify JNK3 as a regulator of β cell function and survival and suggest that targeting this pathway may enhance incretin-based therapies www.jci.org/articles/vie...
January 3, 2026 at 11:14 AM
New data identify tanycytic cilia as key sensors regulating energy balance in a sex-dependent manner www.biorxiv.org/content/10.6...
January 1, 2026 at 5:00 PM
May you and your friends and family enjoy good health, happiness, respect, democracy, competent governance, safety, adventure, access to sufficient food, housing, equality of opportunity and peace in 2026
December 31, 2025 at 8:02 PM
The ongoing interest in #diabetes clusters continues along the road to personalized medicine #T2D diabetesjournals.org/diabetes/art...
December 30, 2025 at 9:42 PM
After an exhausting few days, now back at home, Santa catches up on new data for GLP-1 medicines, and one of his personal interests, Age-related macular degeneration and #weightloss therapies. Santa (almost) never gets tired of TriNetX data www.sciencedirect.com/science/arti...
December 27, 2025 at 7:18 PM
Real world data from TriNetX #cancer assessing the safety of GLP-1 medicines and key outcomes in the context of immune checkpoint inhibitor therapy in people with #T2D www.sciencedirect.com/science/arti...
December 27, 2025 at 4:43 PM
Glucagon exerts a positive chronotropic effect in the isolated mouse heart via GCGR & via HCN channels in the sinus node. Glucagon-containing GLP-1 medicines are on the way, reminding us of the species-specific differences in cardiac GCGR expression 🧪#Obesity #MASH www.mdpi.com/1422-0067/27...
December 27, 2025 at 4:38 PM
By studying muscle, liver and cerebral cortex tissue responses to intermittent fasting in male mice, the authors highlight therapeutic targets for metabolic, neurodegenerative disorders and #aging www.biorxiv.org/content/10.1...
December 27, 2025 at 12:47 PM
Clinical P1 SAD/MAD evaluation of the long-acting GLP-1R antagonist Imapexitide in healthy human volunteers academic.oup.com/jcem/advance...
December 24, 2025 at 7:49 PM
The latest view from Indianapolis-explaining a component of tirzepatide action #weightloss through a CNS hypothalamic leptin sensitization MOA enabling increased energy expenditure in mice www.biorxiv.org/content/10.6...
December 24, 2025 at 1:38 AM
Amylin activated distributed CNS networks revealed by resting-state fMRI following peripheral amylin administration in wild-type (WT) and receptor-activity modifying protein 1/3 knockout (RAMP1/3 KO) mice
www.sciencedirect.com/science/arti...
December 23, 2025 at 1:08 PM
The GLP-1 medicine field continues to evolve, offering new effective options for people living with #obesity coming to US distribution channels in January 2026 Higher dose oral semaglutide for weight management now FDA approved #weightloss @novonordisk.bsky.social
www.novonordisk.com/content/nnco...
December 22, 2025 at 11:46 PM
Amidated gut hormone peptidergic signaling as a determinant of sex-specific metabolic and behavioral states in Drosophila @MolMetab www.sciencedirect.com/science/arti...
December 20, 2025 at 12:36 PM
Some key endpoints in the Pemvidutide #MASH trial, with comparative analysis to other investigational and approved MASH drugs
December 19, 2025 at 1:43 PM